Lantern Pharma Inc. (LTRN)
NASDAQ: LTRN
· Real-Time Price · USD
3.58
-0.04 (-1.10%)
At close: May 02, 2025, 3:59 PM
3.71
3.63%
After-hours: May 02, 2025, 05:02 PM EDT
-1.10% (1D)
| Bid | 3.28 |
| Market Cap | 38.61M |
| Revenue (ttm) | 100.65K |
| Net Income (ttm) | -20.78M |
| EPS (ttm) | -1.93 |
| PE Ratio (ttm) | -1.85 |
| Forward PE | -3.07 |
| Analyst | Buy |
| Ask | 3.78 |
| Volume | 10,149 |
| Avg. Volume (20D) | 44,927 |
| Open | 3.67 |
| Previous Close | 3.62 |
| Day's Range | 3.51 - 3.60 |
| 52-Week Range | 2.55 - 7.21 |
| Beta | 1.63 |
About LTRN
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In ...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 11, 2020
Employees 24
Stock Exchange NASDAQ
Ticker Symbol LTRN
Website https://www.lanternpharma.com
Analyst Forecast
According to 1 analyst ratings, the average rating for LTRN stock is "Buy." The 12-month stock price forecast is $25, which is an increase of 598.32% from the latest price.
Stock Forecasts4 months ago
+4.27%
Lantern Pharma shares are trading higher after the...
Unlock content with
Pro Subscription
5 months ago
+0.95%
Lantern Pharma shares are trading higher after the company announced LP-184 received its second fast-track designation status from the FDA for the treatment of triple-negative breast cancer.
